Trials / Unknown
UnknownNCT01277627
Influence of Nevirapine on HCV Viral Load
Influence of Nevirapine on HCV Viral Load Among HIV/HCV-coinfected Patients
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Valme University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Nevirapine-based antiretroviral therapy is associated with lower plasma HCV viral load in HIV/HCV-coinfected individuals.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nevirapine | nevirapine: 400 mg a day. |
| DRUG | efavirenz, protease inhibitors | efavirenz: 600 mg a day |
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2012-07-01
- First posted
- 2011-01-17
- Last updated
- 2011-01-17
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT01277627. Inclusion in this directory is not an endorsement.